Metacrine Stock
Metacrine is a privately held biotech company
Sign up today and learn more about Metacrine Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Metacrine Stock
Metacrine is a privately held biotech company founded in 2015 on technology licensed from the laboratory of Dr. Ronald Evans, a world leader in nuclear hormone receptors and Howard Hughes Medical Institute Investigator at the Salk Institute. Metacrine will leverage two mechanistically distinct programs to target diabetes, steatohepatitis and other metabolic and liver disorders.
Investors
ARCH Venture Partners
Grail, Prime Medicine, Aledade, Codiak Biosciences, Mindstrong, Metacrine, Beam Therapeutics
Funding History
| August 2015 | $36.0M |
|---|---|
| December 2017 | $22.0M |
| June 2018 | $65.0M |
Management
CEO
Neil McDonnell
CFO
Trisha Millican
CEO & President
Ken Song
Press
GlobeNewswire (press release) - Jun, 13 2018
Metacrine Completes Dosing of First Cohort in Phase 1 Trial of MET409, a Novel Non-Bile Acid FXR AgonistFinSMEs (blog) - Jun, 8 2018
Metacrine Completes $65M Series C FinancingPR Newswire (press release) - Mar, 7 2018
Metacrine to Present at 30th Annual ROTH Conference and HC Wainwright & Co. 2nd Annual NASH Investor ConferenceThe San Diego Union-Tribune - Dec, 7 2017
Metacrine raises $22M to advance liver drug for humansEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
